



COPY OF PAPERS
ORIGINALLY FILED

Patent
270/070US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Langenfeld, John

Serial No.: 10/044,716

Filed: January 11, 2002

For: BONE MORPHOGENETIC PROTEIN-2
IN THE TREATMENT AND DIAGNOSIS OF
CANCER

Group Art Unit: 1645

Examiner: Not Yet Assigned

RECEIVED
AUG 14 2002
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application

LA-240675.1

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

August 6, 2002
Date of Deposit

Rachel Marquez
Name of Person Mailing Paper

Signature of Person Mailing Paper

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable.

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. **12-2475**.

Dated: _____

8/6/02

LYON & LYON LLP

By: _____


Sandra S. Fujiyama
Reg. No. 46,713



22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP
633 W. Fifth Street, Suite 4700
Los Angeles, CA 90071
Phone: (213) 489-1600
Fax: (213) 955-0440

FORM PTO-1449 	ATTY. DOCKET NO. 272/070US		SERIAL NO. 10/044,716
	APPLICANT: Langenfeld, John		
	FILING DATE: January 11, 2002	GROUP: 1645	

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

**COPY OF PAPERS
ORIGINALLY FILED**

RECEIVED
AUG 14 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	AI						
	AJ						
	AK						

NON PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	AL	Ikeda et al., "Cloning of Rat Type I Receptor cDNA for Bone Morphogenetic Protein-2 and Bone Morphogenetic Protein-4, and the Localization Compared With That of the Ligands," Developmental Dynamics, Vol. 206, (1996) pp. 318-329
	AM	ten Dijke et al., "Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity," Oncogene, Vol. 8, (1993) pp. 2879-1887
	AN	
	AO	

LA-242662.1

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	